Indian Firms Compete On $500mn U.S. Anti-Ulcer Market

Bangalore: After pharma giant Zydus Cadila received approval from the U.S. Food and Drug Administration (FDA) to manufacture Lanzoprazole, an anti-ulcer drug; it has entered the list of generic makers in the $500 million U.S. market, reports Reghu Balakrishnan from Business Standard.

On the other hand, the U.S. FDA has sent approval for Lansoprazole to other Indian firms like Wockhardt, Dr Reddy's and Natco Pharma. According to Wockhardt which received the U.S. FDA approval in 2012, the marketing of Lansoprazole delayed release (DR) Capsules would probably get affected as the export-oriented plant Aurangabad remains under U.S. FDA scanner.

Lansoprazole is a medicine used for treating ulcers and other conditions related to stomach acid. As per the IMS Health data, in 2012 there were sales of $501 million on this product.

Moreover this has resulted in Indian pharma companies facing competition in sales of Lansoprazole from other U.S. companies like Perrigo Pharma.

Also Read:
India Asks U.S. To Stiffen Their Own Laws on Patent Regime
10 Home Based Small Business Ideas for Women